Real-World Healthcare Resource Utilization in Patients with Indolent Non-Hodgkin's Lymphoma: Differences between Patients Treated First-Line with Ibrutinib or Bendamustine plus Rituximab

被引：0
|
作者：
Irwin, Debra [1 ,2 ]
Zhang, Lu [3 ]
Wilson, Kathleen [3 ]
Hoehn, Gerard [4 ]
Szabo, Erika [4 ]
Tang, Boxiong [5 ]
机构：
[1] Truven, Ann Arbor, MI USA
[2] IBM Co, Ann Arbor, MI USA
[3] Truven Hlth Analyt, Cambridge, MA USA
[4] Teva Pharmaceut, Malvern, PA USA
[5] Teva Pharmaceut Inc, Frazer, PA USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-113093
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3549
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Real-world healthcare resource utilization in patients with indolent non-Hodgkin lymphoma: differences between patients treated with first-line ibrutinib or bendamustine plus rituximab
    Irwin, Debra E.
    Wilson, Kathleen
    Hoehn, Gerard
    Min, Stella
    Szabo, Erika
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (03) : 439 - 444
  • [2] Real-world healthcare resource utilization and costs in patients with chronic lymphocytic leukemia: differences between patients treated with first-line ibrutinib or bendamustine plus rituximab
    Irwin, Debra
    Wilson, Kathleen
    Thompson, Stephen
    Choudhry, Azhar
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (04) : 623 - 628
  • [3] Real-World Healthcare Resource Utilization in Patients with Chronic Lymphocytic Lymphoma: Differences between Patients Treated with Ibrutinib or Bendamustine plus Rituximab
    Irwin, Debra
    Zhang, Lu
    Wilson, Kathleen
    Hoehn, Gerard
    Szabo, Erika
    Tang, Boxiong
    [J]. BLOOD, 2018, 132
  • [4] First-line treatment with Bendamustine plus Rituximab for patients with indolent non-Hodgkin's lymphoma or Mantle cell lymphoma: Real-world experience.
    Kotchetkov, Rouslan
    Susman, David
    Gerard, Lauren
    DiMaria, Erica
    Nay, Derek Wayne
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] Real-world incidence and costs of serious infections and cardiovascular complications among patients with indolent non-Hodgkin lymphoma treated with first-line ibrutinib or bendamustine/rituximab.
    Irwin, Debra E.
    Thompson, Stephen
    Ribalov, Rinat
    Choudhry, Azhar
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma
    Hainsworth, JD
    [J]. SEMINARS IN ONCOLOGY, 2003, 30 (01) : 9 - 15
  • [7] Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma
    Hainsworth, JD
    Litchy, S
    Burris, HA
    Scullin, DC
    Corso, SW
    Yardley, DA
    Morrissey, L
    Greco, FA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (20) : 4261 - 4267
  • [8] Updated Results of the Phase III Study of First-Line Bendamustine/Rituximab Versus CHOP plus Rituximab in Patients with Indolent Non-Hodgkin Lymphoma
    不详
    [J]. CLINICAL LYMPHOMA & MYELOMA, 2009, 9 (02): : 128 - 129
  • [9] Differences in Quality of Life Between Bendamustine Plus Rituximab Compared with Standard First-Line Treatments in Patients with Previously Untreated Advanced Indolent Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma
    Burke, John M.
    Van der Jagt, Richard H.
    Kahl, Brad S.
    Wood, Peter
    Hawkins, Tim E.
    MacDonald, David
    Hertzberg, Mark
    Kwan, Yiu-Lam
    Simpson, David
    Craig, Michael
    Kolibaba, Kathryn
    Issa, Samar
    White, Richard E.
    Munteanu, Mihaela C.
    Clementi, Regina
    Chen, Ling
    Flinn, Ian W.
    [J]. BLOOD, 2012, 120 (21)
  • [10] EFFICACY AND SAFETY OF BENDAMUSTINE IN ASSOCIATION WITH RITUXIMAB AS FIRST-LINE TREATMENT FOR PATIENTS WITH INDOLENT NON-HODGKIN LYMPHOMA OR MANTLE CELL LYMPHOMA
    Cencini, E.
    Fabbri, A.
    Iannuzzi, A.
    Schiattone, L.
    Brambilla, C. Zuanelli
    Bocchia, M.
    [J]. HAEMATOLOGICA, 2017, 102 : 112 - 112
12345